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Abstract
Background: Pain is a common and distressing symptom in people with cancer, but is under-recognised and under-
treated. Australian guidelines for ‘Cancer Pain Management in Adults’ are available on the Cancer Council Australia Cancer
Guideline Wiki. This study aims to evaluate the effectiveness and cost-effectiveness of a suite of guideline implementation
strategies for improving pain outcomes in adults with cancer in oncology and palliative care outpatient settings.
Methods: The study will use a stepped-wedge cluster randomised controlled design, with oncology and palliative care
outpatient services as the clusters. Patients will be eligible if they are adults with cancer and pain presenting to participating
services during the study period. During an initial control arm, services will routinely screen patients for average and worst
pain over the past 24 h using a 0–10 numerical rating scale (NRS) and have unfettered access to online guidelines. During
the intervention arm, staff at each service will be encouraged to use: 1) a patient education booklet and self-management
resource; 2) an online spaced learning cancer pain education module for clinicians from different disciplines; and 3) audit
and feedback of service performance on key indices of cancer pain screening, assessment and management. Service-based
clinical change champions will lead implementation of these strategies.
The trial’s primary outcome will be the probability that patients initially screened as having moderate-severe (≥5/10
NRS) worst pain experience a clinically important improvement one week later, defined as ≥ 30% reduction. Secondary
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outcomes will include patient empowerment and quality of life, carer experience, and cost-effectiveness. For the main
analysis, linear mixed models will be used, accounting for clustering and the longitudinal design. Eighty-two patients
per service at six services (N = 492) will provide > 90% power. A qualitative sub-study and analyses of structural and
process factors will explore opportunities for further refinement and tailoring of the intervention.
Discussion: This pragmatic trial will inform implementation of guidelines across a range of oncology and palliative
care outpatient service contexts. If found effective, the implementation strategies will be made freely available on the
Wiki alongside the guidelines.
Trial registration: Registered 23/01/2015 on the Australian New Zealand Clinical Trials Registry (ACTRN12615000064505).
Keywords: Cancer, Pain, Guidelines, Implementation, Translation, Self-management, Patient education, Health professional
education, Audit and feedback, Clinical change champions
Background
Despite of decades of research and practice improvement
initiatives, 39–66% of people with cancer experience pain,
and up to 40% of people with pain receive inadequate an-
algesia [1, 2]. Under-treated pain not only reduces patient
quality of life (QOL) [3] but also increases health service
use and costs [4]. Barriers to pain assessment and man-
agement occur at the levels of the patient (e.g. reluctance
to report pain, misconceptions regarding opioids), clin-
ician (e.g. lack of time and expertise), service (e.g. inad-
equate process for screening) and healthcare system (e.g.
lack of coordination) [5–10]. Routine screening and im-
plementation of evidence-based guidelines can improve
quality of care and outcomes for cancer pain [11–13].
However, clinicians are unlikely to use symptom screening
results or guidelines unless they are motivated and sup-
ported by focused strategies [14, 15].
The current authors have undertaken a program of work
to develop and implement Australian guidelines for ‘Cancer
Pain Management in Adults’, which are now available on-
line via the Cancer Council Australia Cancer Guidelines
Wiki [16, 17]. This program was structured in accordance
with the UK Medical Research Council’s (MRC) Frame-
work for complex interventions, defined as those with mul-
tiple interacting components that need tailoring to local
healthcare settings and other contexts [18, 19]. The MRC
recommends that complex intervention programs consist
of four phases: development, feasibility and piloting, evalu-
ation, and implementation. The development phase of our
program involved a national survey of current practice
[20–22], two systematic reviews [5, 23] and consideration
of the wider literature by an Organising Committee within
a theoretical framework called the Behaviour Change
Wheel [24]. This process identified three strategies showing
promise for improving care processes and outcomes for
cancer pain: patient training, clinician education, and audit
and feedback. These strategies are discussed in detail in the
Methods section of the current paper. Our piloting phase
tested the feasibility of screening for pain and auditing pain
assessment and management in adults attending palliative
care and oncology services [25]. The current paper focuses
on the protocol for the evaluation phase, which aims to test
the effectiveness and cost-effectiveness of all three guideline
implementation strategies combined for improving pain
outcomes in adults with cancer attending oncology and pal-
liative care outpatient services.
Methods/design
Aims
Primary aim
The study’s primary aim is to evaluate capacity for a
suite of three guideline implementation strategies to in-
crease the probability that patients initially screened as
having moderate-severe (≥5) worst pain on a 0–10 nu-
merical rating scale (NRS) will experience a clinically
important improvement of ≥30% one week later.
Secondary aims
Secondary aims are:
1. to evaluate capacity of the three guideline
implementation strategies versus a control arm to:
i. reduce mean worst and average pain severity across
all patients screened as having clinically relevant
(≥2 NRS) or moderate-severe (≥5 NRS) worst pain
from time of screening to one, two and four week
later by half a standard deviation (0.5 SD);
ii. demonstrate a between-arm difference in patient
empowerment in patients screened as having clinically
relevant (≥2 NRS) worst pain, as measured by 0.5 SD
difference on the Health Education Impact
Questionnaire (heiQ) (41) at one, two and four
weeks post-screening;
iii. demonstrate a between-arm difference in the
experiences of unpaid carers of participating patients,
as measured by a 0.5 SD difference on the Carer Ex-
perience Scale (CES) [26] at two and four weeks
post-screening;
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iv. demonstrate a between-arm difference on mean
patient quality of life (QOL), as measured by a
difference of 0.5 SD on the European Organisation
for Research and Treatment of Cancer Palliative Care
(EORTC QLQ C15-PAL) [27] at two and four weeks
post-screening;
2. to evaluate the cost-effectiveness of the three guideline
implementation strategies based on incremental cost
per additional responder on the primary outcome;
3. to inform refinement and tailoring of the
implementation strategies for different service
settings.
Design and setting
The study will use a stepped-wedge cluster randomised
controlled trial (RCT) design, with Australian oncology
and palliative care services as the units of randomisation.
In this design, randomisation concerns the sequence in
which services transition between experimental condi-
tions rather than the condition to which they are allo-
cated (see Fig. 1). Each participating patient and carer
will contribute data to only one arm, not both.
While needing a longer timeline than a parallel cluster
design, a stepped-wedge design has the following advan-
tages for translational research: 1) the design controls for
between-service variation in baseline practice; 2) statistical
power is boosted by the opportunity to assess intervention
effects in a pre/post comparison across services; and 3) as-
sessment of longitudinal effects (i.e. sustainability) can
occur in services that transition earlier [28].
Ethics approval was granted by the South Western Sydney
Local Health District Human Research Ethics Committee
(HREC). Protocol modifications will be submitted to the
HREC for approval, and modifications made to the trial
registry information as needed.
This protocol complies with reporting requirements out-
lined in the cluster RCT extension of the Consolidated
Standards of Reporting Trials (CONSORT) [29] and Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) [30].
Participants
Services
Services will be selected to inform understanding of
intervention effectiveness across services of differing
geographic locations (e.g. state/territories; metropolitan,
regional, rural) and configurations of oncology and pal-
liative care. Study sites are included in the trial’s entry
on the Australian New Zealand Clinical Trials Registry.
Patients
There will be two patient participant populations for this
study. The first will contribute to primary outcome data,
and the second to secondary outcomes. Because the study
is funded by the National Breast Cancer Foundation
(NBCF) of Australia, sampling will aim to recruit ≥60%
patients with breast cancer. It is anticipated that breast
cancer’s prevalence and this population’s proven will-
ingness to participate in clinical trials [31] will make
over-sampling unnecessary.
Participant eligibility criteria will follow recommenda-
tions from the Methods for Researching End of Life Care
(MORECare) initiative [32] by targeting people most
likely to benefit from the intervention. Inclusion criteria
for patients to contribute to primary outcome will be: 1)
attending a participating service as an outpatient during
the study period; 2) having a diagnosis of advanced can-
cer of any type; 3) ability to self-complete a 0–10 NRS
for severity of worst and average pain in English or one
of five widely-spoken languages most commonly associ-
ated with poor English proficiency in Australia (Chinese,
Italian, Greek, Vietnamese and Arabic) [33]; 4) choosing
Fig. 1 Stepped wedge design with staggered introduction of training/intervention in 8 services
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not to opt-out of being contacted one week later to
complete the NRS and giving verbal informed consent
to participate when contacted; and 5) a score of ≥5 on the
NRS for worst pain. Inclusion criteria for patients contrib-
uting to secondary outcomes will be the same as criteria
one, two, three and four above, as well as: 5) a score of ≥2
on the NRS for worst pain; and 6) spoken English
proficiency sufficient to complete secondary outcome
measures.
Patients will be excluded if they have already partici-
pated in the study either at another service taking part in
the trial or at the same service when it was in the control
arm, or are documented as having cognitive impairment
that would preclude capacity to give informed consent.
Potentially eligible patients will be identified by the re-
search team via a review of service pain screening data
(see below), which will include information about their
NRS score, whether they have opted out of being con-
tacted, and their cancer status (completed by clinic
staff ). Patients will be telephoned at home, and the ver-
bal informed consent procedure undertaken.
Carers
Unpaid carers will be eligible if they: 1) are identified by
a patient who has given informed consent to participate
in the study as providing them with substantial emo-
tional and practical support in an unpaid capacity; 2) are
willing to provide verbal informed consent to participate;
and 3) have sufficient spoken English proficiency to
complete a survey and/or interview.
Carers will be excluded if the patient for whom they
provide care does not participate in any secondary out-
come components.
Service staff
Service staff will be eligible to participate if they are: 1)
employed on a permanent basis either full- or part-time
at a participating service in a role that provides clinical
care to patients with cancer pain or front desk adminis-
trative support; and 2) provide informed consent.
Service staff will be excluded if they are working at a
participating service on a casual or agency basis.
Intervention
Each participating service will first be included in the
control arm and then transition to the intervention arm,
defined as follows. Due to the pragmatic nature of the
trial, no limit is placed on other interventions each ser-
vice can undertake during the study period.
Control arm
We will compare the intervention with usual care plus
the introduction of routine screening for pain where this
is not already common practice. The rationale for
including a screening system in the usual care arm is
that this is already routine practice in some oncology
and palliative care services across Australia.
Management and clinicians at participating services will
be made aware of the Australian online guidelines for ‘Can-
cer Pain Management in Adults’ and the study’s aim to test
implementation of these. Services that are already utilising
an electronic or paper-based symptom screening system
will be asked to incorporate the study’s NRS for worst and
average pain over the past 24 h. Where no screening system
is established, services will be equipped with a paper-based
system for symptom screening and providing individual pa-
tient reports for treating clinicians to refer to during con-
sultations. A paper-based rather than electronic screening
system has been chosen because a pilot study conducted by
the current authors found that implementing electronic
screening can be resource-intensive and logistically challen-
ging [25]. Acknowledging that migrants with limited profi-
ciency in their host-country language may be at special risk
of poor outcomes [34], screening measures will be made
available in five widely-spoken languages most commonly
associated with poor English proficiency in Australia
(Chinese, Italian, Greek, Vietnamese and Arabic) [33].
While access to pain screening results and online
guidelines will be unfettered, services will not be
given strategies to encourage or support clinicians in
using these.
The control arm at each service will continue as long
as necessary to recruit the target sample size.
Intervention arm
At the beginning of a training phase, two clinicians at
each service will take on the role of ‘clinical change cham-
pions’ to lead local implementation of the intervention
with support from the project team. Two are needed to
cover any periods of absence. Selection of clinical change
champions will be conducted in partnership with man-
agers at each service. Champions can be of any discipline
and role provided they meet established criteria [35].
Champions will attend training at their service aimed
at tailoring the intervention to local needs and contexts.
Champions will be involved in administering the audit
tool and feeding back data to staff in order to identify
strengths and weaknesses at their service against recom-
mendations in the guidelines. They will also be sup-
ported to identify barriers and facilitators to cancer pain
management and helped to develop solutions. Cham-
pions will be invited to attend monthly teleconferences
with champions at other services to create a community
of practice that will enable knowledge sharing, know-
ledge creation and identity building [36]. The degree to
which champions take on all responsibilities or delegate
these to other staff will be tailored to each service.
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Also during the training phase, all clinical and
reception-desk staff will be given an overview of the
guidelines and implementation resources by the cham-
pions at their service with support from the project team.
During the training phase and for a period of three
weeks afterwards, data will not contribute to outcome
measurement to allow time for the intervention to be-
come established as routine practice.
During the intervention phase, the process for feeding
back individual patient results from screening will be
monitored, with medical teams receiving a summary re-
port of screening data for each patient prior to consult-
ation to inform management, and a copy filed in the
medical record. The process by which this happens will
vary across services according to local systems.
Three implementation strategies will be used to address
commonly reported barriers and facilitators in the most
parsimonious way. Findings from a systematic review sug-
gest that coverage of barriers, rather than number of strat-
egies, may be important in successfully implementing
guidelines [37]. Therefore, one strategy was chosen to
intervene at each of the levels of patient, clinician and
health service, with strategies designed to address barriers
across more than one level wherever possible. See Table 1
for mapping of the strategies against behaviour change
‘functions’ as identified by Michie et al.’s Behaviour
Change Wheel [24].
The patient-level strategy includes a written resource
to help patients report and self-manage their pain, support
coordination and communication between patients and cli-
nicians, and advocate for evidence-based person-centred
care [38]. This resource was designed for use in conjunc-
tion with an education booklet and DVD designed by
members of the current team (ML, FB) called ‘Overcoming
Cancer Pain’, published by Cancer Council Australia [39]
and widely available in Australian oncology and palliative
care services. The booklet includes information on pain,
general advice on non-pharmacological and pharmaco-
logical management, and a pain diary template. The
booklet and DVD were found to reduce pain versus usual
care in a previous RCT [40]. The self-management re-
source includes: 1) a template for setting specific, measur-
able, achievable, relevant and time-bound (SMART) care
goals, as well as identifying potential obstacles and ways to
overcome these, and 2) an action plan detailing exacerbat-
ing and alleviating factors, current pharmacological and
non-pharmacological management strategies, and con-
tacts for support. Interviews with patients have pro-
vided preliminary support for the usefulness of the
self-management resource [38, 41]. Patients and their
physicians will set goals and complete the plan together
to ensure shared understanding and decision-making.
Patients will be encouraged to use the resource as a
patient-held record that they can take to every healthcare
appointment to support communication and ensure that
care is coordinated and centred on their needs.
The strategy selected for the clinician level is a spaced
learning training module for clinicians of different disci-
plines aimed at improving knowledge of guideline rec-
ommendations and applying this within the context of
person-centred care. Spaced learning will be delivered
online using the QStream Healthcare Solutions platform.
The spaced learning format has been shown to significantly
improve knowledge and retention of guideline content in
RCTs [42]. This approach was chosen because it is a feas-
ible form of education within busy clinical environments
and is applicable to all members of multi-disciplinary
teams. Questions testing knowledge of guideline recom-
mendations are delivered to participants via email, which
also provides immediate feedback about whether the ques-
tions have been answered correctly. Incorrect answers are
resubmitted to participants at a later date and only retired
when they have been answered correctly on two occasions.
The use of clinical vignettes in each question ensures that
learning is focused on the needs of an individual patient
rather than only on biomedical aspects. Members of
the current team (JP, TS) have developed and piloted a
spaced learning module for cancer pain assessment in
the palliative care setting, where it was associated with
increased levels of nurse knowledge and documentation
of pain, as well as reduced pain severity for patients
[43, 44]. Further modules are being developed by the
team to test and improve clinician understanding of
cancer pain assessment and management.
At the service level, an audit and feedback mechan-
ism has been chosen as the best strategy following evi-
dence from a Cochrane systematic review that this
strategy can lead to improvement in provider compli-
ance with desired practice [45], including implementa-
tion of cancer pain guidelines [46]. The team adapted
an audit tool developed by Victoria Health, which col-
lects data on key indices of cancer pain care, including
screening, assessment, regular and breakthrough anal-
gesia, and management of adverse effects [47]. During
the pilot phase of this program, the audit tool was found
feasible to implement, and changes were made to improve
inter-rater reliability and relevance to the current inter-
vention [25]. In accordance with best-practice, feedback
will be provided in written (e.g. newsletter) as well as ver-
bal formats and accompanied by discussion aimed at set-
ting and meeting SMART targets via an agreed practice
improvement plan [48]. Discussions will be framed within
a Plan-Do-Study-Act (PDSA) model for quality improve-
ment, with which Australian clinicians are familiar [49].
During a sustainability phase, service clinicians who
are trained in the use of the audit tool will provide the
research team with de-identified audit data on pain as-
sessment and management for patients screened as
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having a severe (≥7 NRS) pain score to assess whether
adherence to guideline recommendations has continued.
Outcomes
The study period for each patient will be four weeks or
until death, whichever is the shorter time. See Table 2
for the enrolment and assessment schedule.
Primary outcome
The primary outcome will relate to both individual pa-
tient and cluster levels and concern the probability that
patients at each service initially screened as having
moderate-severe (≥5 NRS) worst pain will experience a
clinically important improvement one week later, defined
as a ≥ 30% reduction in their original rating.
One week following positive screen is considered suffi-
cient time to allow for comprehensive assessment and
any new treatment regimens to become established. Pain
over the past 24 h was chosen to balance the need to
avoid recall bias with sampling a representative time
window. The NRS is the optimal brief measure of pain
severity based on compliance rates, responsiveness, ease
of use and applicability [50]. The NRS is also the re-
sponse option used by most widely used and validated
multi-dimensional pain scales (e.g. Brief Pain Inventory
[51]). A rating of 5 on a 0–10 NRS has become estab-
lished as the threshold for moderate cancer pain [52].
Patients with pain of this magnitude or higher will form
the focus of the primary endpoint because of the added
urgency of reducing moderate-severe pain versus mild.
A 30% reduction in pain was selected as the minimal
clinically important difference (MCID) based on recom-
mendations for pain trials by the US Food and Drug Ad-
ministration, which takes into account evidence that the
number of NRS points needed for a MCID varies ac-
cording to the baseline score [53].
To minimise selection bias, the study will use an
opt-out procedure for patients’ permission to obtain
their contact details and telephone them one week later
to measure the primary outcome. Upon contact, patients
will be invited to give verbal informed consent to
Table 1 Behaviour change ‘functions’ (Michie et al., 2011 [24]) and related strategies employed to overcome barriers to cancer pain
assessment and management in the Stop Cancer PAIN Trial (adapted from [68])
Behaviour change function Strategies for overcoming barriers to cancer pain assessment and management
Patient level Clinician level Service/system levels
Education - Increasing
knowledge or understanding
Information on types of pain, medications
and side-effects (including low risk of
opioid addiction)
(OVERCOMING CANCER PAIN BOOKLET)
Information on opioid dosage,
conversion and use in patients
who are older and/or have
renal failure
(GUIDELINES, SPACED LEARNING)
Data on prevalence of
cancer pain enabling
comparison between
services (AUDIT)
Persuasion - Using
communication to induce
positive or negative feelings
or stimulate action
Goal setting, reflection on exacerbating/
alleviating factors, management strategies,
when/from whom to seek help aimed
at reframing pain and promoting sense
of control (SELF-MANAGEMENT RESOURCE)
Patient advocacy for
person-centred care
(SELF-MANAGEMENT RESOURCE)
Local data on prevalence of cancer
pain and performance on quality
indicators
(SCREEING, AUDIT)
Data on hospitalisations
and other healthcare costs
resulting from cancer pain
(ECONOMIC EVALUATION)
Incentivisation - Creating
expectation of reward/Coercion
Creating expectation of
punishment or cost
Goal setting, monitoring of pain
(SELF-MANAGEMENT RESOURCE)
Quality improvement targets on pain assessment,
management and outcomes
(AUDIT)
Training - Imparting skills Skills development in rating pain
severity and self-managing pain
(SELF-MANAGEMENT RESOURCE)
Skill development in assessment,
management and providing
patient education (SPACED
LEARNING, SELF-MANAGEMENT
RESOURCE)
Development of service
capacity to routinely
screen for pain (SCREENING)
Environmental restructuring -
Changing the physical or
social context
Encouraging reporting of pain
(SCREENING, SELF-MANAGEMENT
RESOURCE)
Increased focus on cancer pain care
(SCREENING, GUIDELINES, PATHWAY,
AUDIT, SPACED LEARNING,
SELF-MANAGEMENT RESOURCE)
Modelling - Providing an
example for people to aspire
to or imitate
Personal stories of well managed pain
(OVERCOMING CANCER PAIN DVD)
League table (SPACED LEARNING,)
Modelling change
(CLINICAL CHANGE CHAMPIONS)
Community of practice
Enablement - Increasing
means/reducing barriers
to increase capability or
opportunity
Tools for promoting pain reporting,
enhancing doctor/patient communication,
and increasing priority/time accorded pain
(SCREENING, SELF-MANAGEMENT RESOURCES)
Patient-held record supports
information transfer and
care coordination between
providers
(SELF-MANAGEMENT RESOURCES)
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provide primary outcome data, and will remain at liberty
to refuse at this time.
For a flow diagram of recruitment of patients to the
primary outcome component of this study, see Fig. 2.
Secondary outcomes
Secondary outcomes will assume a MCID to be 0.5
standard deviation (SD), using an established rule of
thumb for patient reported outcomes [54].
Patient pain Secondary outcomes for pain will be at the
cluster level and relate to the potential for the interven-
tion versus control arm to result in: 1) mean reduction
for worst pain severity in patients with clinically signifi-
cant (≥2 NRS) and moderate-severe (≥5 NRS) worst pain
from screening to one, two and four weeks later; and 2)
mean reduction for worst and average pain across all
screenings, to give a population measure of effect.
A waiver on patient consent has been authorised by the
HREC to include de-identified pain screening data from
all patients attending services during the control and
intervention arms to avoid selection bias. However, in-
formed consent will be required for participation in all
other secondary outcomes, detailed as follows. The HREC
has approved a verbal (rather than written) consent pro-
cedure for all outcomes except health service utilisation,
for which written informed consent will be required using
a standardised form developed by Medicare.
Patient quality of life Patient QOL will be measured at
weeks one, two and 4 using the EORTC QLQ C15-PAL
[27], a short-form of the EORTC QLQ-C30 [55], which
is among the most widely used cancer-specific QOL
measures. The QLQ C15-PAL includes 15 items to
reduce burden and focus on issues most relevant to
people with advanced cancer. It provides scores for glo-
bal QOL, physical functioning, psychological function-
ing, and symptoms that include fatigue, nausea and
vomiting, breathlessness, insomnia, appetite loss and
constipation. Importantly for this study, it also provides
a score for pain interference and uses a recall period of
the past week; both features will complement the two
pain NRS, which focus on pain severity over the past
24 h. In this study, five additional items from the
QLQ-C30 will be added to the C15-PAL at every admin-
istration to enable cost-utility evaluation using the
QLQ-Utility measure [56]. These items assess physical
functioning, role functioning, social functioning (two
items) and diarrhea.
A MCID of 0.5 SD difference between control and
intervention arms will provide a convenient single esti-
mate that approximates to scale-specific MCIDs devel-
oped for the QLQ C15-PAL [57].
Patient empowerment The Health Education Impact
Questionnaire (heiQ) will be administered at weeks one,
two and 4 to evaluate patient empowerment. A version
of the heiQ developed in Australia specifically for cancer
will be used. The study includes scales measuring health
service navigation, constructive attitudes and approaches
and skill and technique acquisition [58]. As well as offer-
ing an index of self-reported self-management efficacy, it
is hypothesised from our systematic review that patient
empowerment may have a direct impact on pain experi-
ence itself [23].
Carer experience The Carer Experience Scale (CES) will
be administered at weeks two and 4 to evaluate the
intervention effect on unpaid carers in terms of their
Table 2 Enrolment and assessment schedule for patient participants in the Stop Cancer PAIN Trial
STUDY PERIOD
Allocation Post-allocation Close-out
TIMEPOINT 0 Week 1 Week 2 Week 4 tx
ENROLMENT:
Eligibility screen X
Informed consent Opt-out X
Allocation X
ASSESSMENTS:
Patient worst/average pain severity X X X X
Patient quality of life X X X
Patient empowerment X X X
Carer experience X X
Patient and carer interviews X
Patient MBS/PBS data X
MBS Medicare Benefits Schedule, PBS Pharmaceutical Benefits Scheme
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relationship with patients, support received and ability
to carry on with their own lives [26].
Structural and process measures The implementation
strategies evaluated by this study represent a complex
intervention involving multiple interacting components
[18]. As such, measures of infrastructure and processes
for care are needed to assess fidelity of implementation,
clarify causal mechanisms and identify influential con-
textual factors to inform further refinement and tailoring
to different settings.
Service-level process measures are: screening rates,
clinician training (via spaced learning and other initia-
tives), adherence to the guidelines, and documentation
quality.
Staff-level process measures are: the amount of time
spent in training and on cancer pain screening, assess-
ment and management by clinical staff and front desk
administrative staff. Staff will be invited to complete an
anonymous online survey that asks them their role at
the service and three separate questions on how much
time they spent on cancer pain screening, assessment
and management during their last complete work day.
Patient-level process measures are: number of consulta-
tions, multi-disciplinary input, primary care support, and in-
dices of care recommended by the guidelines. Items of
particular interest will be instances of screening, assessment,
patient education, regular analgesia, breakthrough analgesia
and management of side-effects (preventative and treat-
ment). The audit tool (administered by trained personnel to
standardise between arms and services) will assess partici-
pants’ clinical records retrospectively. Because it is often not
documented in medical records, patients’ receipt of pain
education will be measured by asking the patient at each
time-point they contribute to secondary data collection.
Descriptive/control variables Patient variables will in-
clude demographics, details of cancer diagnoses, perform-
ance status (Australia - modified Karnofsky Performance
Status [AKPS] [59] at palliative care services and the Eastern
Oncology Cooperative Group Performance Status [ECOG]
[60] at oncology services) and comorbidities that may cause
pain or influence its management (e.g. renal impairment).
Carer variables will include demographics and relationship
to the patient. Staff variables will be limited to role.
Qualitative sub-study
A sample of patients and carers (n = 20 respectively)
who participate in secondary outcome measurement will
be invited to take part in interviews 4 weeks after initial
screening. Interviews will use a focused question route
and ask about informants’ experiences of pain
Fig. 2 Study diagram of patient recruitment and data collection for primary endpoint of worst pain over past 24 h at one week after screening
with worst pain of ≥5 on a 0–10 numerical rating scale (NRS)
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assessment and management, self-management educa-
tion, and perceived person-centredness and coordination
of care.
On completion of the intervention arm at each service,
clinicians and front desk administrative staff will be invited
to participate in interviews or focus groups to explore per-
ceived barriers and facilitators to the intervention.
Data management
A designated staff member at each site will enter baseline
screening data into an Excel spreadsheet specifically devel-
oped for this study. Participants will be identified by a study
number only, and data will be stored in a locked filing cabi-
net or on password-protected computers at the coordinat-
ing site. The investigators and sponsor will have access to
the final dataset. Because the intervention arm is aimed at
encouraging clinicians to provide evidence-based care ra-
ther than use a novel intervention, no data monitoring
committee is required. There are no plans for independent
trial audit. In the event that unexpected adverse events are
associated with the conduct of the trial, incident reports
will be completed by the project team and updates pro-
vided to the HREC. Participant information sheets will pro-
vide contact details for complaints. Trial results will be
communicated to the research and clinical communities via
journal publication and conference presentation, to which
the investigators and (where appropriate) representatives
from participating services will contribute as authors.
Sample size
To assess the appropriate study sample size and compute
study power, we used a computer simulation allowing for
20% dropout by both services and patients. Drawing on
data from 1612 consecutive patients [61], outcome data
were generated to mimic pain scores we expect to see in
the presenting population. We generated data from a beta
distribution (scaled 0 to 1), rescaled to lie between 0 and
10, and then rounded to integer values. We then discarded
data points < 2 to represent the sample of interest. We
allowed service-specific means to vary between 0.05 and
0.15 to generate an appropriate intra-class correlation. We
used a standard MCID of 0.5 effect size [62]. To more
closely represent reality, we allowed for variation in the re-
sponses of each patient to intervention. Once a hypothet-
ical study population had been generated, we ran a linear
mixed model that included an intervention effect as well
as an intervention by time effect, as well as a random
service effect. We repeated this whole process several
hundred times and then estimated power by computing
the proportion of times that the null hypothesis would be
rejected. We did this both for the main intervention effect,
as well as the intervention by time effect. Two-sided hy-
pothesis tests with type I errors of 0.05 were used. Assum-
ing 82 patients per service at six services (N = 492), our
study will have > 90% power to detect the main effect. The
study will oversample by two services (i.e. a total of 8
services) and 18 patients per service (i.e. n = 100 at each
service) to allow for drop-out.
Randomisation
Randomisation will be conducted at a central office by a
statistician (LL) not involved in the operation of the
study. A random sequence will be generated using a
computerised randomisation algorithm. Allocation will
be based on clusters rather than individuals, and ran-
domisation will be concerned with the time at which
each service transitions from the control arm to training
and intervention. Randomisation will occur prior to data
being collected at each service. Due to the nature of the
intervention, concealment of allocation is not feasible.
Stratification will be unnecessary because each service
will serve as its own control. Patients will be automatic-
ally allocated to control or intervention arms according
to the current arm of their treatment service upon their
first presentation.
Randomisation will be conducted by the trial statistician
(LL). Services will be enrolled by members of the project
team prior to randomisation after a contract is signed by
service managers. No concealment will be feasible for
managers and clinicians due to the nature of the trial de-
sign and intervention. Because randomisation is con-
cerned with the time at which each service will commence
the intervention, individual patients and caregivers will be
enrolled after randomisation but will be unaware of ser-
vice allocation at the time of their enrolment.
Blinding
The nature of the intervention in this study renders blind-
ing of clinicians impractical, and previous research suggests
that uptake of guidelines in the control arm will be unlikely
in the absence of targeted strategies of the kind to be intro-
duced in the intervention arm [14]. Information for patients
will provide only general information about the aims of the
study (i.e. that it will compare different approaches to
cancer pain management) rather than specifics of the de-
sign and intervention. Previous experience of cluster RCTs
by the current team suggests that attempts to blind re-
search assistants collecting data will be impractical. Instead,
attention will be paid to research assistant training and
standardisation of data collection as ways to limit the
potential for bias. Personnel conducting analyses will be
blinded to service allocation.
Statistical methods
For the main analysis, linear mixed models [63] will be used
to model the outcomes of interest, while accounting for the
clustering and longitudinal design. We have conducted
computer simulations to confirm that this approach will
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work well for pain NRS scores measured on an eleven point
scale. The linear mixed modeling framework is very flexible.
For example, it will allow for testing whether treatment ef-
fects diminish over time. It will also allow the incorporation
of additional covariates of interest, for instance patient age,
gender, ethnicity and factors related to disease; and inclu-
sion of covariates that reflect characteristics of the study
services. Statistical analysis will be performed using ap-
propriate software capable of handling data from this
study design. Analyses will be repeated for all patients
and patients newly referred during the intervention
arm to control for the possibility that outcomes are in-
fluenced by care received prior to the intervention be-
ing implemented. For secondary patient outcomes,
analyses will be repeated for patients with clinically
relevant (≥2 NRS) and moderate-severe (≥5 NRS) worst
and average pain.
Economic analysis
An economic evaluation will estimate the incremental costs
and consequences of the intervention versus control arm.
The primary outcome for the cost-effectiveness analysis will
be the incremental cost per additional responder, with re-
sponse defined as a clinically important improvement of
30% on a 0–10 NRS one week post-screening for those
with moderate-severe (≥5 NRS) worst pain). The incremen-
tal cost per additional quality adjusted life years (QALY)
will be the secondary outcome. Utility scores will be derived
from the EORTC QLQ-C15-PAL and 5 additional items
from the QLQ-C30 (mapped from QLQ-Utility [56]) and
index values for carers from the CES. Survey responses will
be linked to health service utilisation data accessed through
the Centre for Health Record Linkage (CHeReL) and
from Commonwealth datasets (Medicare Benefits Scheme
(MBS); Pharmaceutical Benefits Scheme [PBS]) and hospital
records. Variables will include: Australian Refined Diagnosis
Related Groups (ARDRG) code; number of hospitalisations;
length of hospital stays; number of emergency department,
outpatient, psychology/psychiatry and general practitioner
(GP) visits; health insurance status; medication usage. Costs
of the intervention will relate to the screening systems im-
plemented at each service, materials for training, and staff
time spent on attending training and screening, assessing
and managing cancer pain. As economic data may be
skewed, confidence intervals will be estimated with boot-
strap methods [64]. Sensitivity analysis will examine the
effect of assumptions and determine which cost compo-
nents drive the results.
Qualitative analysis
Interview and focus group data will be transcribed
verbatim and imported into NVivo 11 software for ana-
lysis. Analysis will use an integrative qualitative method
designed specifically for informing health service
interventions [65]. This method uses both deductive and
inductive approaches to ensure themes build on previous
research whilst also remaining open to new insights from
participants’ experiences. To reduce risk of bias and
enrich interpretation, analysis will be conducted by two
independent researchers who will then meet to agree
themes. As well as coding concepts (concept codes),
researchers will also code relationships between concept
codes (relationship codes), participants’ positive or nega-
tive appraisals (participant perspective codes) and relevant
variables relating to participant characteristics (participant
characteristic codes) and service (service codes). Prelimin-
ary themes will be subject to review by the larger research
team before finalizing the code structure.
The Promoting Action on Research Implementation in
Health Services (PARiHS) framework will be applied to
analyses of interview/focus group data and the structural
and process measures outlined above to consider the
influences of evidence, context and facilitation on the
success of the intervention [66].
Discussion
The protocol for the Stop Cancer PAIN Trial has been
designed to balance the need for rigorous evaluation
with the flexibility required by complex interventions
[67]. The proposed intervention is intended to take a co-
ordinated approach to overcoming barriers to guideline
implementation at system, provider and patient levels in
order to ensure that care for cancer pain meets a
best-practice standard across each service but can also
be tailored to the needs of individual patients and
families.
One of the advantages of a stepped wedge design over
parallel cluster RCTs is that a diversity of services can be
included without compromising comparability because
each cluster serves as its own control. Inclusion of hetero-
geneous services in the proposed study should enable gen-
eralisability of results to a large proportion of Australian
oncology and palliative care services. Our qualitative
sub-study and analyses of structural and process factors
will provide useful insights into the requisite conditions
for the intervention to succeed and modifications needed
for different service models.
The study’s methods are limited by a lack of blinding,
which is necessitated by the nature of the design, interven-
tion and outcomes. Standardised procedures for eligibility
screening are designed to reduce the risk of selection bias
that might arise from clinician and researcher knowledge
of allocation. Logistic barriers will mean that sustainability
assessment beyond the intervention arm period will be
limited to audit data at the service level, rather than out-
come measurement at the patient level. Sustainability of
effects on patient and carer outcomes, therefore, will at
best be inferred rather than directly observed. There is
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also a risk that practical issues relating to service availabil-
ity and recruitment may make the randomisation schedule
difficult to adhere to with regard to the order in which
each cluster commences the control arm and transitions
to the intervention [68]. The main purpose of the ran-
domisation is to ensure that not all services commence at
the same time and so limit any confounding that might
occur from changes at the national level (e.g. policy) that
coincide with transition from control to intervention
arms. The precise order in which services commence and
transition may be of lesser concern in terms of likely bias.
If implementation strategies are found to be cost-effective,
they will be made available free-of-charge alongside the
Australian guidelines for 'Cancer Pain Management in
Adults' on the Cancer Council Australia Cancer Guide-
lines Wiki [16] to facilitate nationwide translation. In
keeping with the continuous cycle recommended for
complex interventions by the MRC, the Wiki platform
will enable ongoing development and incorporation of
changing evidence over time.
Other information
Registration
The trial was prospectively registered on the Australian
New Zealand Clinical Trials Registry on 23rd January
2015 with the trial identification ACTRN12615000064505;
World Health Organisation unique trial number U1111–
1164-4649. The primary sponsor is The University of
Sydney. TL is the contact for public and scientific queries:
Tim Luckett; T + 61 2 9514 4861; E tim.luckett@uts.edu.au
Protocol version number and date
I001/V 5, 5th April 2017.
Roles and responsibilities
Decisions for the conduct of the trial are made by the
Stop Cancer PAIN Trial Executive Committee (ML, TL,
MA, JP). The trial is coordinated from IMPACCT (Im-
proving Palliative, Aged and Chronic Care through
Clinical Research and Translation) from the University
of Technology Sydney. An Advisory Group meets twice
yearly to identify synergies with other initiatives across
Australia.
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